FDA approves CYRAMZA® (ramucirumab) for EGFR-mutated non-small cell lung cancer
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
List view / Grid view
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
Phase 1 data supports the use of image-guided therapy for difficult to treat cancer...